Download PDF
Diabetes aktuell 2013; 11(7): 315-319
DOI: 10.1055/s-0033-1363512
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Retinaerkrankungen bei Diabetes mellitus – Definitionen und Therapieoptionen

Diabetic retina complications – Definition and therapy
Matina Economopoulou
1   Klinik und Poliklinik für Augenheilkunde,
,
Triantafyllos Chavakis
2   Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl-Gustav-Carus an der Technischen Universität Dresden
› Author Affiliations
Further Information

Publication History

Publication Date:
02 December 2013 (online)

Also available at
   Permissions and Reprints

Die Retinakomplikationen beim Diabetes mellitus sind die diabetische Retinopathie und die diabetische Makulopathie. Erstere wird in die nicht-proliferative diabetische Retinopathie, bei der das Hauptmerkmal die Regression der Retinagefäße ist, und in die proliferative diabetische Retinopathie mit Gefäßneubildung eingeteilt. Bei der diabetischen Makulopathie kommt es durch Hyperpermeabilität der Gefäße zu einem Ödem im Bereich der Makula. Gefäßneubildung und Hyperpermeabilität werden hauptsächlich durch den vaskulären endothelialen Wachstumsfaktor (VEGF) induziert. VEGF-antagonisierende Wirkstoffe treten deswegen immer mehr in den Vordergrund der Retinakomplikationen des Diabetes mellitus.

Diabetic retina complications are diabetic retinopathy and diabetic macular edema. Diabetic retinopathy includes non-proliferative retinopathy, the hallmark of which is vascular regression and proliferative retinopathy that presents with excessive retinal neovascularization. Vascular hyperpermeability is crucial in diabetic macular edema. Neovascularization and vascular hyperpermeability are induced to a large extent by vascular endothelial growth factor (VEGF). Therefore, VEGF-antagonists play an increasing role in the therapy of diabetic retina complications.

Key words

Diabetic retina complications - retinopathy - macular edema - VEGF-antagonists
 

  • Literatur

  • 1 Kempen JH, O'Colmain BJ, Leske MC et al. The prevalence of diabetic retinopathy among adults in the United States. Archives of ophthalmology 2004; 122: 552-563
    CrossrefSearch in Google Scholar
  • 2 Wilkinson CP, Ferris 3rd FL, Klein RE et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110: 1677-1682
    CrossrefSearch in Google Scholar
  • 3 Nationale Versorgungsleitlinie, Typ 2 Diabetes, Prävention und Therapie von Netzhautkomplikationen, Version 2.6.2010.
  • 4 ETDRS group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Archives of ophthalmology 1985; 103: 1796-1806
    CrossrefSearch in Google Scholar
  • 5 AAORV Panel. Prefered Practice Pattern Guidelines. Diabetic Retinopathy 2012;
    Search in Google Scholar
  • 6 Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Archives of ophthalmology 1984; 102: 520-526
    CrossrefSearch in Google Scholar
  • 7 Fong DS, Aiello L, Gardner TW et al. Retinopathy in diabetes. Diabetes care 2004; 27 (Suppl. 01) 84-87
    CrossrefSearch in Google Scholar
  • 8 Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Archives of ophthalmology 1984; 102: 527-532
    CrossrefSearch in Google Scholar
  • 9 DCCT Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
    CrossrefSearch in Google Scholar
  • 10 UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
    CrossrefSearch in Google Scholar
  • 11 van Leiden HA, Dekker JM, Moll AC et al. Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study. Diabetes care 2002; 25: 1320-1325
    CrossrefSearch in Google Scholar
  • 12 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713
    CrossrefSearch in Google Scholar
  • 13 Chew EY, Ambrosius WT, Davis MD et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-244
    CrossrefSearch in Google Scholar
  • 14 Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-1697
    CrossrefSearch in Google Scholar
  • 15 Hammes HP, Feng Y, Pfister F, Brownlee M. Diabetic retinopathy: targeting vasoregression. Diabetes 2011; 60: 9-16
    CrossrefSearch in Google Scholar
  • 16 Hammes HP, Lin J, Wagner P et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 2004; 53: 1104-1110
    CrossrefSearch in Google Scholar
  • 17 Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circulation research 2010; 107: 1058-1070
    CrossrefSearch in Google Scholar
  • 18 Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Seminars in immunopathology 2008; 30: 65-84
    CrossrefSearch in Google Scholar
  • 19 Chavakis T. Interactions of Leukocytes with the Endothelium in the Retina. Hammes HP (Hrsg). Front Diabetes. Karger 2010;
    Search in Google Scholar
  • 20 Kim SY, Johnson MA, McLeod DS et al. Neutrophils are associated with capillary closure in spontaneously diabetic monkey retinas. Diabetes 2005; 54: 1534-1542
    CrossrefSearch in Google Scholar
  • 21 Joussen AM, Murata T, Tsujikawa A et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. The American journal of pathology 2001; 158: 147-152
    CrossrefSearch in Google Scholar
  • 22 Miyamoto K, Khosrof S, Bursell SE et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 10836-10841
    CrossrefSearch in Google Scholar
  • 23 Joussen AM, Poulaki V, Le ML, Koizumi K et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB Journal 2004; 18: 1450-1452
    Search in Google Scholar
  • 24 Johnson MW. Etiology and treatment of macular edema. American journal of ophthalmology 2009; 147
    Search in Google Scholar
  • 25 Sapieha P, Hamel D, Shao Z et al. Proliferative retinopathies: angiogenesis that blinds. The international journal of biochemistry & cell biology 2010; 42: 5-12
    CrossrefSearch in Google Scholar
  • 26 Lang GE. Diabetic macular edema. Ophthalmologica 2012; 227 (Suppl. 01) 21-29
    CrossrefSearch in Google Scholar
  • 27 Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report no. 4. The Early Treatment Diabetic Retinopathy Study Research Group. International ophthalmology clinics 1987; 27: 265-272
    CrossrefSearch in Google Scholar
  • 28 Network DRCR. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1-10
    CrossrefSearch in Google Scholar
  • 29 Elman MJ, Aiello LP, Beck RW et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117
    Search in Google Scholar
  • 30 Nguyen QD, Brown DM, Marcus DM et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789-801
    CrossrefSearch in Google Scholar
  • 31 Mitchell P, Bandello F, Schmidt-Erfurth U et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625
    CrossrefSearch in Google Scholar
  • 32 Holash J, Davis S, Papadopoulos N et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99: 11393-11398
    Search in Google Scholar
  • 33 Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012; 119: 1658-1665
    CrossrefSearch in Google Scholar
  • 34 DOG Bu. Leitlinie Nr20 Diabetische Retinopathie. 2011
    Search in Google Scholar
  • 35 Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. Archives of ophthalmology 1985; 103: 1644-1652
    CrossrefSearch in Google Scholar
  • 36 Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978; 85: 82-106
    Search in Google Scholar
  • 37 Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98 (Suppl. 05) 766-785
    CrossrefPubMedSearch in Google Scholar
  • 38 Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Archives of ophthalmology 2012; 130: 1145-1152
    CrossrefSearch in Google Scholar